Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis

84Citations
Citations of this article
94Readers
Mendeley users who have this article in their library.

Abstract

Context: Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. Design, Setting, and Objectives: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (QCT) with finite element analysis (FEA) and dual-energy x-ray absorptiometry (DXA) with hip structural analysis (HSA). Participants: Participants were women aged 55-80 yr with BMD T-scores -2.0 or less to -5.0 or greater (n = 93). Intervention: Oral ibandronate 150 mg/month (n = 47) or placebo (n = 46) was administered for 12 months. Outcome Measures: The primary end point was total hip QCT BMD change from baseline; secondary end points included other QCT BMD sites, FEA, DXA, areal BMD, and HSA. All analyses were exploratory, with post hoc P values. Results: Ibandronate increased integral total hip QCT BMD and DXA areal BMD more than placebo at 12 months (treatment differences: 2.2%, P = 0.005; 2.0%, P = 0.003). FEA-derived hip strength to density ratio and femoral, peripheral, and trabecular strength increased with ibandronate vs. placebo (treatment differences: 4.1%, P < 0.001; 5.9%, P < 0.001; 2.5%, P = 0.011; 3.5%, P = 0.003, respectively). Ibandronate improved vertebral, peripheral, and trabecular strength and antero-posterior bending stiffness vs. placebo [7.1% (P < 0.001), 7.8% (P < 0.001), 5.6% (P = 0.023), and 6.3% (P < 0.001), respectively]. HSA-estimated femoral narrow neck cross-sectional area and moment of inertia and outer diameter increased with ibandronate vs. placebo (respectively 3.6%, P = 0.003; 4.0%, P = 0.052; 2.2%, P = 0.049). Conclusions: Once-monthly oral Ibandronate for 12 months improved hip and spine BMD measured by QCT and DXA and strength estimated by FEA of QCT scans. Copyright © 2009 by The Endocrine Society.

Cite

CITATION STYLE

APA

Lewiecki, E. M., Keaveny, T. M., Kopperdahl, D. L., Genant, H. K., Engelke, K., Fuerst, T., … Fitzpatrick, L. A. (2009). Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism, 94(1), 171–180. https://doi.org/10.1210/jc.2008-1807

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free